Developer docs
API playgroundTry for free, no card

Search company profiles

Vesigen Therapeutics

Full company profile

uuid0000xdl

Namestring
Vesigen Therapeutics
Legal namestring
Vesigen Therapeutics
Websiteurl
vesigentx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vesigen Therapeutics was a Cambridge, Massachusetts-based, privately held biotechnology company founded in 2019 that developed a non-viral drug delivery platform based on ARMMs (ARRDC1 Mediated Microvesicles), an engineered human extracellular vesicle technology licensed from Harvard University. The platform was designed to transport signaling molecules between cells and deliver therapeutic cargoes—including proteins, RNA-based therapies, and CRISPR-Cas genome editing complexes—to targeted cell types with high encapsulation efficiency and reduced off-target effects. The company's primary research focus was the application of this delivery system to neurodegenerative conditions, with particular emphasis on Friedreich's Ataxia, supported in part by a 2023 General Research Grant from the Friedreich's Ataxia Research Alliance (FARA).

Vesigen's competitive positioning rested on a technology architecture that was described as biocompatible, redosable, simpler to manufacture than viral vectors, tissue-targetable through appended cell-targeting molecules, and capable of carrying large, diverse cargoes. The company was backed by a syndicate that included Leaps by Bayer (Bayer Healthcare LLC), Morningside Group, Alexandria Venture Investments, and Linden Lake Ventures, following a $28.5 million Series A financing in July 2020. Leadership consisted of CEO Paulash Mohsen, co-founder Quan Lu, and director Lucio Iannone, with an organizational footprint of 11–50 employees.

On March 26, 2025, Turn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen, including the Harvard University license and related intellectual property. Following this transaction, Vesigen's operating status is recorded as acquired, and its technology now sits within Turn Bio's pre-clinical epigenetic reprogramming pipeline. As a result, Vesigen no longer operates as an independent commercial entity, and no standalone revenue, product pricing, or go-to-market mechanics were disclosed in the source data.

Short descriptiontext

Vesigen Therapeutics was a Cambridge, MA-based pre-clinical biotech (founded 2019) that developed the ARMMs extracellular vesicle platform, licensed from Harvard, for non-viral delivery of gene-editing therapeutics targeting neurodegenerative diseases such as Friedreich's Ataxia, before being acquired by Turn Biotechnologies in March 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug delivery technology, extracellular vesicles, non-viral gene therapy, CRISPR delivery platform, biopharmaceutical therapeutics
Industry4 codes
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Drug Delivery Platform
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vesigen Therapeutics developed the ARMMs (ARRDC1 Mediated Microvesicles) platform, a non-viral delivery technology based on engineered human extracellular vesicles licensed from Harvard University. The platform was designed to deliver therapeutic cargoes including CRISPR-Cas genome editing complexes, proteins, and RNA-based therapies to targeted cells, with primary applications in treating Friedreich's Ataxia and other neurodegenerative conditions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Vesigen Therapeutics is a biotechnology company that developed the ARMMs (ARRDC1 Mediated Microvesicles) technology - a non-viral drug delivery platform using engineered human extracellular vesicles. The company was focused on applying this delivery technology for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions. The technology was licensed from Harvard University and has since been acquired by Turn Biotechnologies. The company's primary research direction was targeted genome editing therapeutics for Friedreich's Ataxia.

Product and service1 record
1ARMMs (ARRDC1 Mediated Microvesicles) Platform
CategoryDrug Delivery Technology Platform
Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-26
Description

Vesigen Therapeutics developed the ARMMs technology under a license from Harvard University. The technology is based on ARRDC1-Mediated Microvesicles derived from human extracellular vesicles.

2Turn Biotechnologies
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-26
Description

Turn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen Therapeutics. This transfer included the license to the technology from Harvard University and all related intellectual property.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-14
Description

Vesigen received a FARA General Research Grant to develop a targeted genome editing therapeutic strategy for Friedreich's Ataxia. The company will evaluate its ARMM technology as a delivery vehicle for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions associated with FA.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Codiak BioSciences
TypeDirect peer
Description

Developed exosome-based therapeutic platforms (engEx) for delivering diverse cargoes including RNA, proteins, and gene editors. Direct competitor to Vesigen's ARMMs extracellular vesicle approach with similar cargo flexibility and target-tissue ambitions.

TypeDirect peer
Description

Engineering extracellular vesicles (exosomes) for delivery of nucleic acids, proteins, and gene editors to specific tissues. Closest direct peer in modality, platform architecture, and target indications including CNS diseases.

TypeDirect peer
Description

Clinical-stage RNA medicines company using LNP and other delivery systems to enable mRNA, siRNA, and CRISPR-based therapeutics. Comparable in the RNA delivery space and in targeting rare genetic diseases including Friedreich's Ataxia.

TypeDirect peer
Description

Develops non-viral lipid nanoparticle-based gene therapy delivery platforms for both rare and large patient populations. Direct peer in pursuing non-viral alternatives to AAV for gene therapy cargoes.

TypeBroad incumbent
Description

Clinical-stage in vivo CRISPR/Cas9 gene editing company with proprietary LNP delivery for liver-targeted therapies. Broader incumbent in the gene editing space that Vesigen's ARMMs platform could complement or compete with.

TypeBroad incumbent
Description

Clinical-stage genome editing company using both AAV and non-viral delivery approaches for in vivo and ex vivo therapies. Larger incumbent pursuing the same therapeutic cargo space as Vesigen's platform.

TypeDirect peer
Description

Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics, with partnerships across the gene therapy and mRNA industries. Key competitor in non-viral delivery of RNA and gene editing cargoes.

8Laronde (now part of Sail Biomedicines)
TypeEmerging player
Description

Developed endless RNA (eRNA), a closed-loop RNA therapeutic platform with proprietary delivery. Emerging peer pursuing non-viral delivery of RNA-based cargoes, with overlapping strategic intent to Vesigen's RNA delivery applications.

TypeEmerging player
Description

Clinical-stage company developing in vivo base editing therapies for cardiovascular disease, using LNP-based delivery of gene editing cargoes to the liver. Comparable in cargo class (gene editors) and non-viral delivery approach.

TypeEmerging player
Description

Develops cell-derived exosome-based therapeutics (CAP-2003) for inflammatory and rare diseases. Comparable in using extracellular vesicles as a therapeutic delivery modality, with overlap in rare disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vesigen Therapeutics

Biotechnology Drug Delivery Platformvesigentx.com

Vesigen Therapeutics was a Cambridge, MA-based pre-clinical biotech (founded 2019) that developed the ARMMs extracellular vesicle platform, licensed from Harvard, for non-viral delivery of gene-editing therapeutics targeting neurodegenerative diseases such as Friedreich's Ataxia, before being acquired by Turn Biotechnologies in March 2025.

What Vesigen Therapeutics does

Vesigen Therapeutics was a Cambridge, Massachusetts-based, privately held biotechnology company founded in 2019 that developed a non-viral drug delivery platform based on ARMMs (ARRDC1 Mediated Microvesicles), an engineered human extracellular vesicle technology licensed from Harvard University. The platform was designed to transport signaling molecules between cells and deliver therapeutic cargoes—including proteins, RNA-based therapies, and CRISPR-Cas genome editing complexes—to targeted cell types with high encapsulation efficiency and reduced off-target effects. The company's primary research focus was the application of this delivery system to neurodegenerative conditions, with particular emphasis on Friedreich's Ataxia, supported in part by a 2023 General Research Grant from the Friedreich's Ataxia Research Alliance (FARA).

Vesigen's competitive positioning rested on a technology architecture that was described as biocompatible, redosable, simpler to manufacture than viral vectors, tissue-targetable through appended cell-targeting molecules, and capable of carrying large, diverse cargoes. The company was backed by a syndicate that included Leaps by Bayer (Bayer Healthcare LLC), Morningside Group, Alexandria Venture Investments, and Linden Lake Ventures, following a $28.5 million Series A financing in July 2020. Leadership consisted of CEO Paulash Mohsen, co-founder Quan Lu, and director Lucio Iannone, with an organizational footprint of 11–50 employees.

On March 26, 2025, Turn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen, including the Harvard University license and related intellectual property. Following this transaction, Vesigen's operating status is recorded as acquired, and its technology now sits within Turn Bio's pre-clinical epigenetic reprogramming pipeline. As a result, Vesigen no longer operates as an independent commercial entity, and no standalone revenue, product pricing, or go-to-market mechanics were disclosed in the source data.

Vesigen Therapeutics firmographics

Firmographics
Name
Vesigen Therapeutics
Legal name
Vesigen Therapeutics
Website
https://vesigentx.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
Vesigen Therapeutics was a Cambridge, MA-based pre-clinical biotech (founded 2019) that developed the ARMMs extracellular vesicle platform, licensed from Harvard, for non-viral delivery of gene-editing therapeutics targeting neurodegenerative diseases such as Friedreich's Ataxia, before being acquired by Turn Biotechnologies in March 2025.
Ownership category
akta.pro rank

Vesigen Therapeutics industry classification

Industry
Product category
Biotechnology Drug Delivery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Drug delivery technology
  • Extracellular vesicles
  • Non-viral gene therapy
  • CRISPR delivery platform
  • Biopharmaceutical therapeutics

Where Vesigen Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Vesigen Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Vesigen Therapeutics product offering

Product offering

Core offering

Vesigen Therapeutics developed the ARMMs (ARRDC1 Mediated Microvesicles) platform, a non-viral delivery technology based on engineered human extracellular vesicles licensed from Harvard University. The platform was designed to deliver therapeutic cargoes including CRISPR-Cas genome editing complexes, proteins, and RNA-based therapies to targeted cells, with primary applications in treating Friedreich's Ataxia and other neurodegenerative conditions.

Product overview

Vesigen Therapeutics is a biotechnology company that developed the ARMMs (ARRDC1 Mediated Microvesicles) technology - a non-viral drug delivery platform using engineered human extracellular vesicles. The company was focused on applying this delivery technology for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions. The technology was licensed from Harvard University and has since been acquired by Turn Biotechnologies. The company's primary research direction was targeted genome editing therapeutics for Friedreich's Ataxia.

Differentiator

Problem solved

Functional benefit

Products and services

  • ARMMs (ARRDC1 Mediated Microvesicles) Platform

Companies that use Vesigen Therapeutics

Customer profile

Ideal customer profiles1 record

Vesigen Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vesigen Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Harvard UniversitycoreOEM/ Whitelabel/ Licensing Partner · 26 March 2025Vesigen Therapeutics developed the ARMMs technology under a license from Harvard University. The technology is based on ARRDC1-Mediated Microvesicles derived from human extracellular vesicles.
  • Turn BiotechnologiescoreOEM/ Whitelabel/ Licensing Partner · 26 March 2025Turn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen Therapeutics. This transfer included the license to the technology from Harvard University and all related intellectual property.
  • FARA (Friedreich's Ataxia Research Alliance)coreStrategic or Co-development Partner · 14 March 2023Vesigen received a FARA General Research Grant to develop a targeted genome editing therapeutic strategy for Friedreich's Ataxia. The company will evaluate its ARMM technology as a delivery vehicle for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions associated with FA.

Recent moves4 records

Expansion highlights3 records

Vesigen Therapeutics competitors and assessment

Company assessment

Direct peers

  • Codiak BioSciences: Developed exosome-based therapeutic platforms (engEx) for delivering diverse cargoes including RNA, proteins, and gene editors. Direct competitor to Vesigen's ARMMs extracellular vesicle approach with similar cargo flexibility and target-tissue ambitions.
  • Evox Therapeutics: Engineering extracellular vesicles (exosomes) for delivery of nucleic acids, proteins, and gene editors to specific tissues. Closest direct peer in modality, platform architecture, and target indications including CNS diseases.
  • Arcturus Therapeutics: Clinical-stage RNA medicines company using LNP and other delivery systems to enable mRNA, siRNA, and CRISPR-based therapeutics. Comparable in the RNA delivery space and in targeting rare genetic diseases including Friedreich's Ataxia.
  • Generation Bio: Develops non-viral lipid nanoparticle-based gene therapy delivery platforms for both rare and large patient populations. Direct peer in pursuing non-viral alternatives to AAV for gene therapy cargoes.
  • Acuitas Therapeutics: Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics, with partnerships across the gene therapy and mRNA industries. Key competitor in non-viral delivery of RNA and gene editing cargoes.

Broad incumbents

  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company with proprietary LNP delivery for liver-targeted therapies. Broader incumbent in the gene editing space that Vesigen's ARMMs platform could complement or compete with.
  • Editas Medicine: Clinical-stage genome editing company using both AAV and non-viral delivery approaches for in vivo and ex vivo therapies. Larger incumbent pursuing the same therapeutic cargo space as Vesigen's platform.

Emerging players

  • Laronde (now part of Sail Biomedicines): Developed endless RNA (eRNA), a closed-loop RNA therapeutic platform with proprietary delivery. Emerging peer pursuing non-viral delivery of RNA-based cargoes, with overlapping strategic intent to Vesigen's RNA delivery applications.
  • Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies for cardiovascular disease, using LNP-based delivery of gene editing cargoes to the liver. Comparable in cargo class (gene editors) and non-viral delivery approach.
  • Capricor Therapeutics: Develops cell-derived exosome-based therapeutics (CAP-2003) for inflammatory and rare diseases. Comparable in using extracellular vesicles as a therapeutic delivery modality, with overlap in rare disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Vesigen Therapeutics social profiles

Digital presence

Vesigen Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vesigen Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Vesigen Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vesigen Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesigen Therapeutics

What does Vesigen Therapeutics do?

Vesigen Therapeutics developed the ARMMs (ARRDC1 Mediated Microvesicles) platform, a non-viral delivery technology based on engineered human extracellular vesicles licensed from Harvard University. The platform was designed to deliver therapeutic cargoes including CRISPR-Cas genome editing complexes, proteins, and RNA-based therapies to targeted cells, with primary applications in treating Friedreich's Ataxia and other neurodegenerative conditions.

Is Vesigen Therapeutics a public or private company?

Vesigen Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Vesigen Therapeutics founded?

Vesigen Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is Vesigen Therapeutics based?

Vesigen Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Vesigen Therapeutics's main competitors?

Direct peers on record are Codiak BioSciences, Evox Therapeutics, Arcturus Therapeutics, Generation Bio and Acuitas Therapeutics. Broad incumbents are Intellia Therapeutics and Editas Medicine. Emerging players are Laronde (now part of Sail Biomedicines), Verve Therapeutics and Capricor Therapeutics.

Does Vesigen Therapeutics have an API?

No public API is recorded for Vesigen Therapeutics.

What industry is Vesigen Therapeutics in?

Vesigen Therapeutics's product category is Biotechnology Drug Delivery Platform. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTurn Biotechnologies erwirbt vesikuläre ARMMs-Technologie, um den Zugang zu Gewebetargets für seine Therapien zur epigenetischen Reprogrammierung zu verbessernTurn Biotechnologies announced the acquisition of ARMMs (ARRDC1-mediated microvesicles) delivery technology, licensed from Harvard University along with associated assets from Vesigen Therapeutics, to significantly expand the range of organs, tissues, and cells that can be safely and precisely treated with the company's epigenetic reprogramming therapies. The addition of ARMMs complements Turn Bio's existing eTurna LNP delivery platform, enabling the transport of larger and more diverse payloads including gene editors, proteins, and RNA-based therapies, with preclinical data demonstrating effective delivery across retina, lung, nervous system, liver, and spleen tissues. The company stated the technology will accelerate drug candidates in its ophthalmology pipeline and the advancement of TRN-001, a skin rejuvenation therapy.BioSpaceVesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic StrategyVesigen Therapeutics received a General Research Grant from the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing strategy for Friedreich's Ataxia. The company will evaluate its proprietary ARMM technology as a non-viral delivery vehicle for CRISPR-Cas complexes to address the underlying genetic cause of the disease. This marks Vesigen's first grant in neurological disorders.BioSpaceVesigen Therapeutics, Inc. Announces Expansion of Scientific Advisory BoardVesigen Therapeutics expanded its Scientific Advisory Board with appointments of Connie Cepko and Kate Fitzgerald. Cepko brings expertise in retinal diseases, while Fitzgerald contributes to innate immune system research. The company aims to leverage their contributions for its drug discovery programs.citybizVesigen Therapeutics Appoints Rakhshita Dhar to Board of DirectorsVesigen Therapeutics appointed Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, to its Board of Directors. This appointment adds global life sciences and investment expertise to the board as the company advances its drug discovery programs towards clinical trials.BioSpaceVesigen Therapeutics Appoints Paulash Mohsen as Chief Executive OfficerVesigen Therapeutics appointed Paulash Mohsen as CEO on April 11, 2022. He previously served as Chief Business Officer at Yumanity Therapeutics and Country Manager at Cubist Pharmaceuticals. The company develops ARMMs delivery technology for intracellular drug delivery.PR NewswireVesigen Therapeutics Presents Data on Recent Advances to its Engineered ARMMs Therapeutic Delivery Platform at ISEV 2021Vesigen Therapeutics presented new data at the 2021 International Society for Extracellular Vesicles Annual Meeting demonstrating the therapeutic potential of its ARMMs (ARRDC1 Mediated Microvesicles) delivery platform through two virtual poster presentations. The company showed it can produce and purify engineered ARMMs at scale with high payloading efficiency of approximately 300 molecules per vesicle and 90% enrichment purity. The platform enables intracellular delivery of diverse macromolecular payloads including RNAs, proteins, and gene-editing complexes, positioning it as a versatile non-viral delivery vehicle for therapeutic applications.PR NewswireVesigen Therapeutics Appoints Industry Veteran Dieter Weinand to Board of DirectorsVesigen Therapeutics announced the appointment of Dieter Weinand, a veteran life sciences executive, to its Board of Directors. Weinand brings over three decades of pharmaceutical industry experience, including former roles as CEO of Bayer Pharma AG, Executive Vice President at Sanofi, and positions at Pfizer, Bristol Myers Squibb, and Otsuka. He currently serves as Chairman of ZielBio and Replimune Group Inc. in addition to his new role at Vesigen.PR NewswireVesigen Therapeutics Announces Issuance of U.S. Patent for Broad Applications of ARMMs TechnologyVesigen Therapeutics announced on March 16, 2021 that the USPTO issued U.S. Patent No. 10,945,954 for ARRDC1-mediated microvesicles (ARMMs), exclusively licensed from Harvard University. The patent broadly covers ARMMs compositions containing enzymatic payloads, including those for enzyme replacement therapy. CEO Robert Millman said the patent strengthens Vesigen's intellectual property estate and enables a pipeline for CNS, oncology and ocular applications.PR NewswireVesigen Therapeutics Names Lucio Iannone to Board of DirectorsVesigen Therapeutics announced the appointment of Dr. Lucio Iannone, Senior Director of Venture Investments at Leaps by Bayer, to its Board of Directors. This addition aims to leverage Iannone's global life sciences perspective and investment expertise to guide Vesigen's target expansion and preclinical development for its ARMMs technology. The move underscores strategic support from key board members including representatives from Morningside Ventures and Leaps by Bayer.FinSMEsVesigen Therapeutics Raises USD28.5M in Series A FundingVesigen Therapeutics raised $28.5M in Series A financing led by Leaps by Bayer and Morningside Ventures. The company will use the capital to build its ARMMs platform and advance therapeutic agents into preclinical and clinical development.